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Abstract
Background: New pharmacological therapies are challenging the healthcare systems, and there is an increasing need 
to assess their therapeutic value in relation to existing alternatives as well as their potential budget impact. 
Consequently, new models to introduce drugs in healthcare are urgently needed. In the metropolitan health region of 
Stockholm, Sweden, a model has been developed including early warning (horizon scanning), forecasting of drug 
utilization and expenditure, critical drug evaluation as well as structured programs for the introduction and follow-up 
of new drugs. The aim of this paper is to present the forecasting model and the predicted growth in all therapeutic 
areas in 2010 and 2011.
Methods: Linear regression analysis was applied to aggregate sales data on hospital sales and dispensed drugs in 
ambulatory care, including both reimbursed expenditure and patient co-payment. The linear regression was applied 
on each pharmacological group based on four observations 2006-2009, and the crude predictions estimated for the 
coming two years 2010-2011. The crude predictions were then adjusted for factors likely to increase or decrease future 
utilization and expenditure, such as patent expiries, new drugs to be launched or new guidelines from national bodies 
or the regional Drug and Therapeutics Committee. The assessment included a close collaboration with clinical, clinical 
pharmacological and pharmaceutical experts from the regional Drug and Therapeutics Committee.
Results: The annual increase in total expenditure for prescription and hospital drugs was predicted to be 2.0% in 2010 
and 4.0% in 2011. Expenditures will increase in most therapeutic areas, but most predominantly for antineoplastic and 
immune modulating agents as well as drugs for the nervous system, infectious diseases, and blood and blood-forming 
organs.
Conclusions: The utilisation and expenditure of drugs is difficult to forecast due to uncertainties about the rate of 
adoption of new medicines and various ongoing healthcare reforms and activities to improve the quality and 
efficiency of prescribing. Nevertheless, we believe our model will be valuable as an early warning system to start 
developing guidance for new drugs including systems to monitor their effectiveness, safety and cost-effectiveness in 
clinical practice.
Background
During the last decades of the 20th century, several new
and effective drugs have gained widespread use in the
treatment of major diseases such as cardiovascular dis-
eases, depression and diabetes mellitus [1]. These drugs
markedly decreased mortality, shortened hospital stay
and improved the quality of life for large groups of
patients. In recent years, science has witnessed break-
throughs in molecular genetics, proteomics and combi-
national chemistry [2-4]. These advances have triggered
the development of biotechnological methods for the
design and production of drugs to be used in the diagno-
sis or therapy of chronic diseases. Consequently many
new "biological" drugs have been developed and presently
account for 15% of all New Chemical Entities (NCE) or
Biological Entities registered annually in US [5]. These
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drugs are usually considerably more expensive than tradi-
tional drugs.
The increasing expenditures for new drugs place con-
siderable pressure on healthcare systems in their efforts
to continue to provide comprehensive care [6,7]. As a
result, new models for introduction of expensive medi-
cines are urgently needed to avoid prohibitive increases
in taxes or health insurance premiums. Such models
should include early warning systems (horizon scanning),
forecasting of drug utilization and expenditure, critical
drug evaluation to help define which patient groups will
benefit most from the new medicine, and follow-up to
ascertain whether the new drugs are cost-effective in
practice.
In the metropolitan health care region of Stockholm,
Sweden, a new model to introduce new drugs in health-
care was established in 2007 [8]. The concept is operated
through the Regional Drug and Therapeutics Committee
(DTC) in Stockholm (LÄKSAK) and includes:
- Early detection (horizon scanning) of drugs to be
launched during the coming years
- Forecasting of drug utilization and expenditure
- Critical drug evaluation
- Guidelines for the introduction of medicines, prefera-
bly including protocols to assess their value in practice
(effect, safety and cost-effectiveness)
- Retrospective quality assessments using observational
data
- Communication and involvement of DTC members
and professional quality networks, prescribers, patients
and other stakeholders at the regional, national and inter-
national level
- Continuous monitoring of utilization and expenditure
for drugs in hospitals and ambulatory care
- If needed, further educational activities to enhance
appropriate prescribing
This paper presents our forecasting model for drug uti-
lization and expenditures, and the predicted growth in
different therapeutic areas in the Stockholm region in
2010 and 2011. In addition, we present explanatory fac-
tors behind the predicted changes in expenditures. We
believe this model will be of interest also for other regions
and countries when planning for the future.
Methods
The forecasting included a prediction of future expendi-
ture in all therapeutic areas based on a linear regression
analysis applied to historical sales pattern, subsequently
adjusted for factors likely to influence utilization and/or
expenditure.
Linear Regression Analysis
Linear regression analysis was applied to aggregate sales
data from the National Corporation of Swedish Pharma-
cies on hospital sales and dispensed drugs in ambulatory
care, including both reimbursed expenditure and patient
co-payment. The method of statistical analysis was cho-
sen since the forecasting was based on annual data with-
out seasonal dependencies. We had previously
ascertained there were no long term cyclical patterns
during few years included. In addition, the resulting
residuals from the regression analysis did not show any
particular patterns. Consequently, applying time series
models without any such patterns would give approxi-
mately the same results since the auto-correlations will be
estimated to about zero.
Annual expenditures and volumes for all pharmacolog-
ical groups at the 3rd ATC (Anatomical Therapeutic
Chemical Classification) level [9] between 2006 and 2009
were included in the analysis. Expenditure was measured
in Swedish Crowns (SEK) (1 Eur = 10.0 SEK, March 2010)
and volumes in Defined Daily Doses (DDD) [9]. A linear
regression model was applied to each time series of four
observations 2006-2009. The crude predictions for the
coming two years 2010 and 2011 were based on linear
extrapolation. These were then adjusted for factors likely
to increase or decrease future utilization and expendi-
ture, such as patent expiries, new drugs to be launched or
new guidelines from national bodies or the regional Drug
and Therapeutics Committee (Table 1, [10-15]). The indi-
vidual impact of these factors in each pharmacological
group is presented in the results section. No specific
adjustments were made for the ageing of the population,
population growth and financial incentives for drug pre-
scribing since these changes were already covered by the
original trends.
New Drug therapies or changed indications for old 
therapies
New therapies were identified through horizon scanning.
This is a systematic process to identify new medicines or
new indications of existing medicines that are expected
to receive marketing authorisation from the Regulatory
Authority in the near future and to estimate their poten-
tial impact on patient care [16]. Information on drugs
likely to be launched during the coming two years was
collected from a number of sources. These included pub-
lished reports and websites from regulatory agencies, the
European Commission and the FDA, the UK organiza-
tions for horizon scanning (National Horizon Scanning
Centre in Birmingham and National Prescribing Centre
in Liverpool) and the pharmaceutical industry through
pipeline information on their public websites, as well as
formal face to face meetings with different pharmaceuti-
cal companies.
Review and modification of forecasting based on expert 
input
All the information collected was discussed and priori-
tized in consultation with each of the 23 medical and sci-Wettermark et al. BMC Health Services Research 2010, 10:128
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Table 1: Factors likely to influence future utilization and expenditure considered in the forecasting model.
Factor Estimated impact on 
expenditure
Comment
Decreasing expenditure
Patent expiries and the subsequent 
introduction of generics
50-90% decrease In Sweden, since generic substitution was introduced in 2002, reimbursed 
prices for generics have been decreasing down to 10 to 20% of the price of 
the original brand within a year after patent expiry [10,11]. Since it may take 
a year for the prices to decrease by 90%, we estimated expenditure for a 
drug on an annual basis to be reduced by 50% the first year after patent 
expiry. We have not applied the same estimates for biosimilars since these 
are not considered interchangeable and questions still remain about their 
clinical efficacy, safety, and immunogenicity [12].
Changes in prices and reimbursement 
status
0-20% decrease All existing drugs are currently being reviewed by the Swedish Dental and 
Pharmaceutical Benefits Agency (TLV) (value-based pricing for existing 
drugs) [10]. Individual assessment was performed for each planned 
reimbursement review since the impact of them has been variable.
Increasing expenditure
Likely new drugs to be launched and 
new indications for existing drugs
0-x% increase The potential impact on the healthcare budget was assessed based on 
estimates of likely/anticipated price for each new product, target patient 
populations and time for diffusion. Target populations were estimated 
based on the prevalence and/or incidence of the diseases and conditions or 
procedures for which each new medicine was likely to be prescribed. Data 
on the prevalence and incidence were collected from various published and 
unpublished sources including the Swedish National hospital discharge 
register, the National prescribed drug register, databases from the County 
Council, and published scientific studies [13].
Variable impact
New guidelines from national 
authorities or the regional DTC [11].
+/-5% annual change Some guidelines were considered to increases in utilization, e.g. National 
Guidelines for diabetes suggesting stricter targets for HbA1c. Other 
guidelines were suggested to decrease utilization, e.g. regional guidelines 
for stricter management of infectious diseases. Overall, guidelines were 
predicted to have a limited impact during the first two years since prior 
studies have shown that guidelines are slowly adopted in the healthcare 
system [14].
Introduction of incentives and 
budgets for drug prescribing along 
with greater scrutiny of prescribing
+/-0 The regional budgetary model that had been applied for a number of years 
included voluntary financial incentives for primary care practices linked to 
the level of adherence to the DTC recommendations and local assessment 
of prescribing performance in a "prescribing quality report" [15]. A decision 
had been taken to allocate strict drug budgets for primary care in 2011. 
However, at the time when the forecasting was performed, it was not clear 
how it should be constructed. Budgets have also been introduced for 
ambulatory care prescribing from hospitals. These budgets are, however, 
only partly allocated and to certain drugs. Consequently, we have not 
predicted the change in budgeting system to have any impact on the 
overall trends for 2010-2011.
Major structural changes in healthcare 
provision, organization and 
reimbursement
0-3% annual increase A number of structural changes were expected to take place during 2010-
2011. A reform increasing patient access to primary healthcare was 
expected to increase the prescribing of antibiotics, analgesics and 
antiasthmatics by 3% while changes in access to community pharmacies 
(state monopoly for pharmacies replaced by new law opening up for private 
pharmacies) were not expected to influence net expenditure during 2010-
2011.Wettermark et al. BMC Health Services Research 2010, 10:128
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entific expert groups belonging to the DTC system in the
Stockholm County [10]. These expert groups cover dis-
eases of organ systems e.g. cardiovascular, gastrointesti-
nal and neurological disorders. Each group has members
representing all major specialist clinics in the county as
well as a general practitioner, a clinical pharmacologist
and a pharmacist. All involved experts have to apply a
strict policy for declaration of interests including con-
tacts with the pharmaceutical industry [10]. Finally, the
forecasting models were scrutinized and modified after
input from joint workshops with expert groups and after
final input and comments from the main authors, who
have extensive clinical pharmacological and/or pharma-
cotherapeutic knowledge or experience. The final fore-
casting report for 2010-2011 was published in Swedish in
March 2010.
Results
Overall forecasting results
In 2009, the total drug expenditure for the Stockholm
County was 6.9 billion SEK, corresponding to 3.490 SEK
or  €349/inhabitant. This increased by 3.3% compared
with 2008 (Figure 1). We predict that the total expendi-
ture, including both ambulatory and hospital sales, will
increase by 2.0% in 2010 and by 4.0% in 2011.
The expenditure is predicted to increase for all major
therapeutic areas (Figure 2); most predominantly for anti-
neoplastic and immunomodulating agents (ATC L) as
well as drugs for the nervous system (ATC N), infectious
diseases (ATC J) and blood-forming organs (ATC B).
In particular, large increases are expected for "biologi-
cal" drugs, such as TNF-alpha inhibitors and monoclonal
antibodies, and small molecules for targeted cancer ther-
apy. We also estimate that expenditure will increase rap-
idly for some drugs used for common diseases, i.e. drugs
prescribed for pain, asthma and diabetes, as well as anti-
coagulants. This is due to the launch of new medicines, as
well as increasing overall volumes without expected sav-
ings from new patent expirations. Table 2 contains data
on the changes envisaged for all therapeutic groups.
Alimentary tract including antidiabetic agents (ATC-group 
A)
We expect the expenditures for anti-ulcer drugs to
decrease by 5% in 2010 and 3% in 2011 due to patent
expiries and decreasing prices for proton pump inhibi-
tors. The impact of lower prices on the overall expendi-
tures will to some extent be counteracted by increasing
volumes, although reimbursement restrictions by TLV
(Table 1) may limit such an increase [10].
Considerable increases are expected for antidiabetic
agents excluding insulin (13% in 2010 and 9% in 2011)
due to the increased prevalence of type 2 diabetes [17],
new National Guidelines suggesting stricter targets for
HbA1c, and the introduction of several new drugs (the
GLP-I agonists exenatide and liraglutide, as well as the
DPP-4 inhibitors sitagliptin, vildagliptin and saxagliptin)
[18]. We anticipate that the safety problems observed for
glitazones in patients with ischemic heart disease [19]
may contribute to a more rapid introduction of the DPP-
IV inhibitors for add-on therapy in patients with type 2
diabetes not controlled on traditional sulphonyl ureas
and metformin. On the other hand, there are also antici-
pated safety problems with these drugs [20]. There is a
need for new antidiabetic drugs, but their place in ther-
apy will depend on their long-term safety and effective-
ness suggesting a need for the step wise introduction of
these NCEs. It is likely that the net increase for all antidi-
abetic agents will remain at 4% due to the moderation in
sales of long-acting insulin as a result of new recommen-
dations in national guidelines and the observational stud-
ies demonstrating a potential association between insulin
glargin and the development of breast cancer [21].
The ATC group A also includes orphan drugs for
patients suffering from rare enzyme deficiencies, e.g.
Gaucher's disease. In Europe, orphan drug status can be
granted when the prevalence of the disease does not
exceed 5 cases per 10 000 inhabitants [22]. Since 2000,
when the ad hoc legislation came into force, up to 2007,
out of 528 designated orphan indications related to 400
orphan medicinal products (OMP) only 45 (44 drugs)
were approved (8.5%) [22]. Access to these drugs varies
greatly both between and within countries, mainly
because of the high annual cost of treatment (up to € 300
000 per patient) [22]. We predicted the expenditure for
orphan drugs within ATC group A to increase by 10% in
2010 and by 9% in 2011.
Blood and blood forming organs (ATC B)
The expenditure for anticoagulants is likely to decrease
by 9% in 2010 and increase by 17% in 2011. The decrease
predicted for 2010 is explained by the patent expiry for
clopidogrel in November 2009. In March 2010, the price
for generic clopidogrel had fallen by 90% compared to the
originator price before patent expiry. The subsequent
increase in expenditure in 2011 is partly explained by the
introduction of dabigatran, rivaroxaban and apixaban
[23]. The clinical development of these new anticoagu-
lants is following the well tested strategy of dose-ranging
and registration studies for short-term use after major
orthopaedic surgery, prior to the development for long-
term use in atrial fibrillation. Phase III trials for stroke
prevention in patients with atrial fibrillation (AF) are
ongoing or recently presented (e.g. RE-LY, Aristotle,
Rocket, Borealis and Averroes) [24,25]. Rapid increases in
drug expenditure can be anticipated if these drugs will
replace warfarin for large numbers of patients [24]. A
potential argument for the new more expensive anticoag-Wettermark et al. BMC Health Services Research 2010, 10:128
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Figure 1 Historical (2006-2009) and predicted (2010-2011) drug expenditures for the Stockholm County Council. Hospital sales and dis-
pensed drugs in ambulatory care, including reimbursed expenditure and patient co-payment.
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Figure 2 Historical and predicted drug expenditures 2010 and 2011 (forecast in February 2010) for all pharmacological groups (ATC 1st lev-
el) in Stockholm County Council.
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ulant drugs is that increasing drug expenditure may be
counteracted by substantial savings in other areas of
healthcare if less coagulation control is needed. However,
our current opinion is that these drugs also need to be
monitored due to the narrow therapeutic margin of anti-
coagulants, and for the purpose of monitoring compli-
ance. Another factor contributing to the expected
increase in antithrombotic drug expenditure is longer
treatment periods with clopidogrel in combination with
low dose acetylsalisylic acid if the European Guidelines
for cardiovascular prevention proposing 12 months treat-
ment [26] are to be adhered to. However, our National
Guidelines recommend 3 to 12 months co-treatment and
most patients receive shorter co-treatment periods.
Lastly, the introduction of prasugrel and tigacrelor may
also influence expenditure. Prasugrel has been intro-
duced at a 50% higher price than the original clopidogrel
(Plavix), and has recevied reimbursement for treatment
of patients with stent thrombosis despite clopidogrel
treatment only; this restriction is challenged by the com-
pany. However, we do not anticipate that prasugrel will
cause major expenses during 2010-2011. Ticagrelor was
shown to be superior to clopidogrel in the PLATO study
[27], and will presumably be launched in 2011. Its future
place in the therapeutic arsenal is so far unclear.
Expenditure for erythropoietin may be reduced due to
the introduction of biosimilars but we have not fore-
casted any major changes in drug expenditure for this
group of drugs due to the ongoing uncertainty about dif-
ferences in biological activity [12]. This may change as
more data becomes available about the safety and efficacy
of the biosimilars in practice, as well as any significant
differences in price between biosimilars and originators
in hospital or ambulatory care.
Cardiovascular drugs (ATC C)
The total expenditure for cardiovascular drugs has
remained stable between 2002 and 2009 despite increas-
ing volumes. This is mainly explained by patent expiries
and generic availability for some high volume drugs such
as simvastatin, amlodipine, enalapril and ramipril during
a period when few new drugs were launched [10]. It is
likely that expenditures will continue to decrease during
the coming two years, mainly due to patient expiries for
the angiotensin receptor blockers (ARB's).
As a result of a reimbursement review, ARB's are only
reimbursed for patients intolerant to ACE-inhibitors
(ACEi) since 2008 [28,29]. This restriction resulted in a
20% decrease in the initiation of ARB while at the same
time the number of patients initiated on ACE-inhibitors
and calcium channel blockers increased [29]. We believe
this change in reimbursement status combined with DTC
educational activities and patent expiry of losartan in
early 2010 will decrease the expenditure for ARB's by 23%
in 2010 and 12% in 2011 (Table 2).
Lipid-lowering agents are the most commonly used
drugs in the population after the antiplatelet agents (i.e.,
mostly low-dose acetylsalicylic acid). In June 2009, the
TLV decided on certain reimbursement restrictions, e.g.
excluding atorvastatin 10 mg and rosuvastatin 5 mg from
the reimbursement scheme [30]. This resulted in a 9%
decrease in expenditures. We believe that the expendi-
tures for lipid-lowering drugs will decrease by a further
6% in 2010, but remain stable after that since there is sub-
stantial pressure to treat to low cholesterol goals (which
will require higher dosages) [31].
Few new cardiovascular drugs will be launched in 2010
and 2011. In 2010, a new antiarrythmic agent, drone-
darone, will be introduced as an alternative to amio-
darone for patients with atrial fibrillation. The drug has in
a large trial (ATHENA) been shown to decrease morbid-
ity and mortality compared to placebo and may, conse-
quently, offer benefits for certain patients [32]. However,
the greater tolerability of dronedarone compared to ami-
odarone is achieved at the expense of lesser efficacy [33],
and the target population for dronedarone has not yet
been defined.
Genito-urinary tract and sex hormones (ATC G)
This group is dominated by sex hormones for contracep-
tion and hormone therapy for climacteric symptoms. The
prescribing of hormone therapy decreased substantially
after publication of the randomized studies HERS and
WHI in 2002 [34,35]. We predict that the use and conse-
quently expenditure will remain stable during the next
couple of years.
The expenditure for drugs for erectile dysfunction is
expected to increase by 9% annually due to increasing
number of men treated. Further increases in this category
of drugs are expected following the launch of the first
drug for premature ejaculation (PE), dapoxetin, in 2009.
This is because PE is the most common male sexual dis-
order, estimated to affect up to 30% of men [36]. These
"lifestyle" drugs have great potential for increased expen-
diture since an international comparison showed that
Sweden had the most rapid diffusion of sildenafil [37].
However, since then, most drugs for erectile dysfunction
have been excluded from reimbursement and there is also
more structured diffusion of these drugs through active
professional involvement, e.g. in DTC activities [10,38].
This has been factored into the forecast model.
Infectious diseases (ATC J)
Substantial increases in expenditures are expected for
antiviral drugs - 9% and 10%, respectively in 2010 and
2011. We anticipate the expenditure for antiviral drugs
will increase due to the continued launch of new drugs
for the treatment of HIV and hepatitis B and C. The num-
bers of patients treated for HIV will increase due to
improved survival and ongoing transmission [39]. Fur-Wettermark et al. BMC Health Services Research 2010, 10:128
http://www.biomedcentral.com/1472-6963/10/128
Page 7 of 14
Table 2: Historical and predicted drug expenditures for 2010 and 2011 in different therapeutic areas.
ATC Therapeutic area Expenditures Forecast Change 2010 Change 2011
2007 2008 2009 2010 2011 MSEK (%) MSEK (%)
A02 Drugs for acid related disorders 143 124 113 107 104 -5 -5% -3 -3%
A10 Drugs for diabetes 194 209 214 223 231 9 4% 8 4%
A Other therapeutic areas 286 286 287 280 293 -7 -2% 13 5%
B01 Anticoagulants 164 180 189 173 202 -16 -9% 29 17%
B02 Coagulation factors 197 212 225 238 249 12 5% 12 5%
B Other therapeutic areas 267 269 268 267 266 -1 0% -1 0%
C09C&D Angiotensin receptor blockers 185 199 204 157 138 -47 -23% -19 -12%
C10 Lipid lowering agents 145 149 140 131 131 -9 -6% 0 0%
C Other therapeutic areas 323 305 301 286 287 -14 -5% 1 0%
D Dermatologicals 161 168 174 177 181 3 2% 4 2%
G Genito Urinary system 374 382 380 388 401 8 2% 13 3%
H Hormones 173 179 186 188 192 2 1% 4 2%
J01 Antibiotics 230 243 250 248 250 -2 -1% 2 1%
J05 Antiviral drugs 205 233 270 294 322 24 9% 28 10%
J Other therapeutic areas 146 151 154 166 175 13 8% 9 5%
L01 & L02 Oncology 521 584 592 591 583 -1 0% -8 -1%
L04AB TNF - alpha inhibitors 304 359 420 473 529 53 13% 56 12%
L Other therapeutic areas 274 328 366 386 415 20 5% 29 7%
M Musculo-skeletal system 194 198 185 187 180 2 1% -7 -4%
N02A&B Analgesics 165 176 189 199 209 10 5% 11 5%
N03 Antiepileptics 122 142 149 157 165 8 5% 7 5%
N05A Antipsychotics 166 177 175 171 167 -4 -2% -4 -2%
N06A Antidepressants 191 187 135 127 127 -8 -6% 0 0%
N Other therapeutic areas 440 481 522 567 619 44 9% 52 9%
P A n t i p a r a s i t i c  p r o d u c t s 1 71 61 51 51 5 0 - 1 % 0 - 3 %
R Respiratory system 477 504 539 565 596 26 5% 30 5%
S Sensory organs 123 138 148 154 160 6 4% 6 4%
V Various 116 125 130 140 148 10 8% 8 6%
A-V ALL DRUGS 6 304 6 702 6 921 7 056 7 336 135 2% 280 4%
Expenditures are presented in million Swedish Crowns (MSEK) (1 Euro = 10.5 SEK).
thermore, the emergence of viruses resistant to current
drugs is driving the need for new antiretroviral agents
[40]. Examples of new drugs include darunavir, maravi-
roc, enfuvirtide and tifuvirtide. Increasing use of combi-
nations of inhibitors that target different steps of the viral
life cycle will also contribute to increasing expenditure.
Increased expenditure is also expected for the treat-
ment of hepatitis. Around 500 new cases of hepatitis C
(HCV) are identified in Stockholm each year. This num-
ber may increase further with the introduction of retro-
spective screening for transfusion-transmitted HCV
infections [41]. The current treatment of chronic HCV
infection consists of a combination of pegylated inter-
feron and ribavirin. New drugs in development include
HCV-specific protease inhibitors, polymerase inhibitors,
immune modulators and ribavirin analogues [42]. Two of
these, thymalfasin and taribavarin, have recently been
launched. The management of chronic hepatitis B (HBV)
has improved over the last decade with the development
of new drugs such as lamivudine, adefovir and dipivoxil,
in addition to interferon (IFN)-alpha therapy [43]. Many
other new drugs are under development which may con-
tribute to increasing expenditure. These have been fac-
tored into the forecast.
The expenditure for antibiotics is predicted to remain
stable in 2010-2011. In June 2009, Strama (the SwedishWettermark et al. BMC Health Services Research 2010, 10:128
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Strategic Programme against Antibiotic Resistance) and
the Swedish Institute for Infectious Disease Control
(SMI) launched the seventh report on the use of antibiot-
ics and resistance in human medicine in Sweden, Swedres
2008 [44]. The use of antibiotics in Sweden is highest
among the elderly and children with prescription rates
varying considerably between different regions. The pro-
portion of children aged 0-6 years treated with at least
one course of antibiotics in 2008 ranged from 38 per cent
in Stockholm county to 25 percent in Västerbotten
county, with a national average of 33 percent.
The use of antibiotics both in primary and secondary
care seems to be changing in a desirable way, with broad
spectrum antibiotics being replaced by narrow spectrum
substances. Various types of penicillins have increased
and the use of cephalosporins and fluoroquinolones is
decreasing. This is in accordance with the guidelines on
the reduction of prescription of fluoroquinolones against
lower urinary tract infections in women, actively pro-
moted by Strama and the DTCs for many years [45].
There is a certain risk that the decreasing utilization will
b e  c o u n t e r a c t e d  b y  a  r e c e n t  r e f o r m  i n c r e a s i n g  p a t i e n t
access to primary healthcare physicians in Stockholm, so
continuous activities are needed. Despite these efforts we
expect that expenditure in secondary care will increase in
the long run due to a continuous increase in the use of
more expensive antibiotics as antimicrobial resistance
develops. This will be factored into future predictions.
We expect the expenditure for vaccines to increase by
7% annually. A number of new vaccines with major
potential for controlling infectious diseases have just
been licensed or are at advanced stages of development.
The predicted increases are mainly attributable to the
introduction of a new seven- and later 13-valent conju-
gate pneumococcal vaccine and the use of subsidized vac-
cines for the prevention of cervical cancer caused by
human papilloma virus (HPV) [46,47]. The decision by
the Swedish National Board of Health and Welfare that
HPV vaccination should be included in the official vacci-
nation program for all girls aged 11-12 years is likely to
increase expenditures by 33 million SEK. Completely new
or significantly modified vaccines may appear in the
future. For the H1N1 influenza, Sweden decided to pro-
mote vaccination for its entire population. The vaccine
cost for Sweden has been estimated at 1.2 to 1.3 billion
SEK and total costs (including administration costs) at
around 2.5 billion SEK [48]. This corresponds to a vac-
cine cost of approximately 0.25 billion SEK for the Stock-
holm region, more than the total expenditure for
analgesics in the region during a year.
Antineoplastic and immunomodulating agents (ATC L)
Increasing expenditure (5% annually) is expected for anti-
neoplastic and immunomodulating agents. The increase
is principally confined to immunomodulating agents as
we do not expect any increase in the total costs for antin-
eoplastic drugs during 2010-2012 for the reasons out-
lined below. The increase is mainly due to the widening
indications for TNF alpha inhibitors and other drugs
already available on the market (Figure 3). Cancer therapy
is characterized by multimodal treatment using surgery,
radiotherapy and a rapidly increasing number of antitu-
mour agents. Today, most agents are introduced for
patients with late stage (metastatic) disease. In many
cases such as for example breast cancer, the efficacy in
metastatic disease translates into increased cure rates
when the new drug is used in earlier stages of the disease
in conjunction with surgery [49,50]. Many drugs are
under development, and both academic institutions and
the pharmaceutical industry are investing in cancer
research at levels previously unseen. All of these factors
contribute to the predicted increase in expenditure over
time, but as discussed below during the time period
2010-2012, this will be counteracted by the patent expira-
tion of several top selling cancer drugs.
Recent advances in the knowledge of the biology of
breast cancer have resulted in targeted treatments, such
as the monoclonal antibody trastuzumab (targeting
HER2-overexpressing cells) [51]. In 2009, trastuzumab
was the top selling oncology drug in our region with total
sales of 72 million SEK, corresponding to € 7.2 million.
However, we predict that the sales will level off during the
coming years since the drug has already reached its target
population in breast cancer. This will be counterbalanced
by trastuzumab recently approved in advanced HER2-
overexpressing gastric cancer. However, there are a more
limited number of patients.
Colorectal cancer, the third most common malignancy
after cancers of the breast and prostate, was treated with
surgery alone until the 1980s when the combination of 5-
fluorouracil and leucovorin was introduced. During the
past ten years, new agents have been introduced and life
expectancy has increased from 5 to 20 months in patients
with metastatic disease [52]. These improvements have,
however, resulted in a dramatic increase in the costs of
medical treatment. In recent years, the addition of biolog-
ical agents like the monoclonal antibodies bevacizumab
as well as cetuximab and panitumumab have further
improved response rates [53]. None of these drugs has,
however, showed activity in the adjuvant setting. Conse-
quently, no major increase in their use in colorectal can-
cer is expected in the period 2010-2012. The overall use
of bevacizumab is expected to increase though mainly
due to other indications including advanced breast, lung
and renal cancer.
Advances in molecular medicine have also provided
insights into the biology of several haematological dis-
eases such as chronic lymphatic leukemia (CLL), chronicWettermark et al. BMC Health Services Research 2010, 10:128
http://www.biomedcentral.com/1472-6963/10/128
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myeloid leukemia (CML), multiple myeloma (MM) and
non-Hodgkin lymphoma (NHL) [54,55]. This has led to
new treatments like the monoclonal antibody rituximab,
which has improved survival rates in patients with
aggressive NHL and become an important therapeutic
option in the treatment of indolent lymphoma [56]. As a
result, Rituximab had the second highest expenditure of
oncology drugs in the region in 2008 helped also by utili-
sation in rheumatoid arthritis (RA - below). We predict
that sales will continue to grow, mainly due to the widen-
ing of indications in haematology (CLL), but also in rheu-
matoid arthritis (see below). Imatinib has become the
backbone of treatment of CML for which several other
drugs ha ve also been approved or are in development.
Dasatinib and nilotinib are presently approved in second
line treatment of CML. If these drugs are approved in
first line treatment, this will have a major impact on costs
as treatment of CML takes place over many years, and
can be considered almost chronic treatment. Bortezomib
is indicated in MM for which there are now also several
new therapeutic options including lenalidomide [54,55].
Increase in the total drug costs for MM is to be expected.
The rapid increase in expenditure due to new drugs is
counteracted by savings due to the introduction of gener-
ics for many oncology drugs. The patent recently expired
for bikalutamide leading to a rapid price decrease. Over
the next two years, patent expiries are expected for sev-
eral of the best selling oncology drugs including aro-
matase inhibitors, docetaxel and temozolamide, resulting
in the expected moderation in growth in 2010 and 2011.
This moderation in growth though is dependant on the
rapid uptake of generics at low prices building on previ-
ous examples [10]. It is also likely that current resource
constraints may increase the need for prioritization of the
utilisation of new oncology drugs with only limited
improvements in survival in most new cancer drugs com-
pared to current treatments and their high prices. This
issue is currently a major focus among health technology
assessment units, and in the evaluation of the actual ben-
efit of new cancer drugs [57].
Expenditure has increased rapidly for the treatment of
rheumatoid arthritis (RA) due to the introduction of anti-
tumor necrosis factor (TNF)-alpha and anti-interleukin
(IL)-1 agents (infliximab, adalimumab, etanercept and
anakinra). Further increases are expected since the indi-
cations have widened and they are increasingly used in
patients with inflammatory bowel disease and psoriasis.
This considerable widening of indications for TNF-alpha
blockers has not though resulted in any price reductions
in Sweden. New drugs are also being introduced for the
treatment of rheumatoid arthritis patients not respond-
ing to conventional treatments, which may also contrib-
ute to increasing expenditures. Such drugs include the
anti-CD20 monoclonal antibody rituximab, which inhib-
its B-cell activity, the T-cell activation inhibitor abatacept,
and other interleukin inhibitors [58].
Nervous system (ATC N)
We predict the expenditure to decrease for antipsychotics
and antidepressants, while it will increase for other CNS
acting drugs (Figure 4).
The expenditure on analgesics has increased by 5-13%
annually the past years due both to increased volumes
and increased prescribing of more expensive products
such as tramadol and oxycodon. This development is
likely to continue despite efforts from the DTC to moder-
ate their use since they are not considered to provide any
advantages over other recommended drugs. New formu-
lations of fentanyl may also contribute to increased
expenditures as well as the new fixed combination of
naloxone and oxycodon. Some savings will be achieved
through patent expiry and the introduction of generics to
sumatriptan. This may, however, partly be counteracted
by increased utilization of triptans. Other drugs for the
treatment of migraine are under development, and it is
likely that the first agonist acting on vascular calcitonin-
gene related peptide (CGRP) receptors, telcagepant, will
be introduced on the market in 2011 [59].
We predict expenditure for antiepileptic drugs to
increase by 5% annually, mainly due to increased utiliza-
tion of lamotrigine and pregabalin for nonepileptic con-
ditions. These include various psychiatric disorders and
pain syndromes [60]. Price competition is weak for these
drugs since it has been decided nationally that they can
not be substituted in pharmacies unlike other generic
drugs [10]. Evidence for their benefit in these conditions
varies though and further studies are needed to be able to
fully determine their place in management. In the USA,
the FDA approved pregabalin for treatment of fibromyal-
gia in June 2007 and the manufacturer filed for the same
indication in Europe. However, EMA didn't approve an
extension of indication for pregabalin to include the
treatment of fibromyalgia [61].
We predict that increase in the expenditure for antipsy-
chotic drugs will moderate over the next two years (Fig-
ure 4). This is mainly due to patent expiry and generic
competition for risperidone. In 2011, we also expect
generics to be introduced for the top-selling drug in the
group, olanzapine. Further savings are unlikely though
due to the commercial pressures to prescribe the single
sourced antipsychotics quetiapine and aripiprazole.
The substantial decrease in expenditure for antidepres-
sants in 2009 is explained by the patent expiry for, and
subsequent introduction of generics to venlafaxine (Fig-
ure 4). With total sales of 58 million SEK in 2008, venla-
faxine accounted for the largest proportion of anti-
depressant expenditure in the region. The sales are
expected to remain stable over the coming years.Wettermark et al. BMC Health Services Research 2010, 10:128
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The expenditure for ADHD-medications is expected to
increase by 33% annually. The increases are expected
both for children and adults. Sweden had earlier a low
utilization of these drugs compared to other western
E uropean countries, mainly due to strict governmental
regulations against the prescription of ADHD medica-
tions [62]. Changes in the legislation may partly explain
the increasing utilization and also that the disease and the
drugs have been heavily discussed in media.
Sensory organs (ATC S)
The increasing expenditure for ophthalmic preparations
has mainly been attributed to the introduction of the vas-
cular endothelial growth factor A (VEGF-A) antagonist
ranibizumab to treat neovascular age-related macular
degeneration [63]. Studies are ongoing with ranibizumab
and other agents for the management of diabetic retinop-
athy and a widening of the indication is likely to occur in
2011.
Discussion
Forecasting pharmaceutical utilization and expenditure
patterns is a complex undertaking. Factors that drive
increases in pharmaceutical expenditures can be divided
into increases in price or in volume (i.e. more users and/
or longer durations of therapy), and changes in utilization
patterns that favour newer, more expensive agents over
older, less expensive yet perhaps equally effective alterna-
tives [64]. Part of the increase may also be attributable to
the introduction of drugs for diseases that were previ-
ously untreatable with existing medications [64].
There are well established methods to predict changes
related to these factors, but the traditional models may
have difficulties in forecasting the uptake of and expendi-
tures for biological drugs [65,66]. Traditional models may
also face problems with reforms and market measures to
obtain lower prices for generics and for interchangeable
brands in a class if these initiatives are new to the health
service. We believe we have addressed both of these
issues in our forecasting model for drug utilization and
expenditure. Furthermore, the process of including local
experts offers the potential to assess early on how
regional diffusion rates of new medicines or adoption of
guidelines are influenced by local therapeutic traditions
and plan for this. Consequently, it is likely that our model
may be more accurate to predict future expenditures than
macro-forecasting performed at the national level. We
would also like to emphasize the importance that the
DTC members are involved and balance and question the
opinions of the members of the expert groups. A DTC
where members have shared evaluation principles and
priorities of value of drugs is important as well as trans-
parent declaration of potential conflict of interests for all
involved experts according to a guideline [10].
The predicted growth in expenditures for 2010 and
2011 is similar to that found by others. Tuffer et al pro-
jected an annual increase of 5,6% in 2010 for prescription
drug expenditures in the US [66]. Slightly lower figures
were predicted for the US market by Hoffman et al who
projected a 0-2% increase in drug expenditures in outpa-
tient settings, a 1-3% increase in expenditures for clinic-
administered drugs, and a 1-3% increase in hospital drug
expenditures for 2009 [65]. The predicted growth in
expenditure is considerable lower than the a 5-7%
increase in drug expenditures in outpatient settings, 12-
14% increase in clinics, and 4-6% increase in hospitals
Figure 3 Historical and predicted drug expenditures 2010 and 2011 for antineoplastic and immunomodulating agents (ATC L) in the Stock-
holm County Council.
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forecasted by Hoffman and colleagues for 2008 [64]. The
moderation is mainly explained by the worldwide eco-
nomic downturn and growing economic uncertainty
[65,66].
The slowdown in growth of ambulatory care drug
expenditure in recent years has largely been attributable
to the increased use of generics through guidance and
financial incentive schemes coupled with market mea-
sures to obtain low prices for generics, and there is cer-
tain evidence that the era of frequent new "blockbuster"
drugs is ending [67-69]. Consequently, the current trend
in drug development seems to be switching to personal-
ized and specialized drugs, which emphasizes the need to
develop new models to introduce drugs in healthcare.
The development may also be influenced by the financ-
ing systems applied in the healthcare system. Financial
incentives have been used for many years in primary care
in the region [15] and no further substantial changes are
expected over the coming years. However, the decision to
introduce strict budgets for all hospitals may influence
both the overall expenditure and the rate of uptake of
new medicines in the future. Financial incentives may
moderate the annual increase in drug expenditure and in
some cases reduce it. Ethical concerns may be raised as
the long term impact of cost containment incentives on
the quality of care has not been thoroughly evaluated [70-
72].
We acknowledge that there are weaknesses in our
model for predicting future drug expenditure. The rela-
tive lack of information on launch dates for new products
and the selective and delayed publication of results from
trials [73] are important problems when trying to esti-
mate the potential value of a new drug and the marketing
strategies to come. The pricing of a new drug is also diffi-
cult to project unless it is merely another competitor in
an established or similar therapeutic class. Early horizon
scanning and long term forecasts (more than a couple of
year s ) wil l t h us  e n ta il c ons ide ra bl e u nc e rta in t y .  R obust
methodologies for horizon scanning [16,74] coupled with
the involvement of local experts who keep abreast of
developments may, however, provide a reasonable basis
for prediction. Other changes in the pharmaceutical mar-
ket are also difficult to predict, both with regard to timing
and effect. For example, estimating patent expiration
dates has become a challenge since these dates may
change due to litigation, additional patents, exclusivities,
and other factors which are difficult to anticipate [75,76].
Another potential limitation is the estimated time for dif-
fusion of new drugs in our model. Diffusion patterns may
change due to increased safety concerns with newly
Figure 4 Historical and predicted drug expenditures 2010 and 2011 for nervous system drugs (ATC N) in the Stockholm County Council.
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approved medications and heightened prescriber sensi-
tivity to the high costs of many new medicines [64]. How-
ever, marketing strategies are also changing, and the
emergence of personalized medicine with very expensive
drugs that are handled by few specialists is creating a new
situation that is difficult to evaluate precisely. We believe
the utilisation of expert groups in our model helps to
address this. Further research is still needed though to
determine the current "life cycles" of various therapies as
well as factors influencing it.
We are convinced that the model presented here can be
developed into more refined models of 'value' based fore-
casting of drug use in a healthcare region. Value based
forecasting can be used to influence treatment patterns
through systematic improvements in the selection of
patients and drugs for specific pharmacotherapeutic
approaches in defined patient populations. Such forecast-
ing may in the future be critical for society to decide pri-
orities and target groups for new expensive treatments or
diagnostic procedures compared to the existing ones [77].
Concerns about unethical priorities regarding treatment
with expensive drugs could in part be resolved by the use
of critical evaluation procedures to elucidate when new
drug treatments may be justified. In addition ahead of
their launch, determine with key groups which patient
populations are likely to most benefit from new drugs and
where costs can be controlled by more rational use of
generics at low prices and/or established patented alter-
natives. Solid forecasts are essential in the process of pri-
oritization. A better "prepared" healthcare system will
have greater chances of releasing or reallocating
resources to help fund valuable new drugs [7,77].
We also believe that it is important to set up registries
for monitoring the use of some of the new drugs in spe-
cific populations (oncology, rheumatology, MS etc). Such
a registry has, for example, been very useful in rheuma-
tology in Sweden [78]. By monitoring the introduction
and use of new very costly drugs in special therapeutic
areas, a better understanding of their patterns of use and
their therapeutic value in practice will be achieved.
Finally , a limitation with our approach is that it only
predicts direct expenditure for drugs. New innovative
therapies may result in savings in other parts of the
healthcare system, such as reduced needs for hospital
care or rehabilitation, or reduce societal costs outside of
the healthcare system [79,80]. In future models also mar-
ginal costs should be considered if other health care costs
such as reduced length of stay, and the need for other
interventions can be included with some degree of cer-
tainty in the estimates. Incorporation of the wider soci-
etal perspective also depends on the ability to transfer
responsibility and funds between budgets including both
health and social care.
Conclusions
We predicted the annual increase in total expenditure for
prescription and hospital drugs to be 2.0% in 2010 and
4.0% in 2011. The utilisation of and expenditure for drugs
is difficult to forecast due to uncertainty about the rate of
adoption of new medicines and various healthcare
reforms and activities to improve the quality and effi-
ciency of prescribing. Nevertheless we believe our model
will be valuable as an early warning system to start devel-
oping guidance for new drugs including systems to moni-
tor their effectiveness, safety and cost-effectiveness in
clinical practice.
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